HTLV-1 Seropositive Patients With Lung Cancer Treated With PD-1 Inhibitors

Cancer Sci. 2020 Jun 18. doi: 10.1111/cas.14536. Online ahead of print.

Abstract

Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell malignancy caused by human T cell leukemia virus-type 1 (HTLV-1).1 Frequent structural variations that disrupt the 3' untranslated region of the programmed cell death-ligand 1 (PD-L1) gene have been found to result in overexpression of PD-L1 in ATL patients.2 The programmed cell death-1 (PD-1)-PD-L1 axis has thus attracted attention as a potential therapeutic target for ATL. However, in a phase 2 trial of the PD-1 inhibitor nivolumab in ATL patients with an increased mutational load and overexpression of PD-L1, the first three patients unexpectedly developed rapid progression of disease after a single dose of nivolumab.

Publication types

  • Letter